Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY: NVO )

85.00 -18.44 (-17.83%)
Official Closing Price Updated: 7:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
68 69 Next >
Why Is MindMed (MNMD) Stock Up 32% Today?
MindMed stock is heading higher on Thursday as MNMD investors celebrate it getting breakthrough designation from the FDA! 
Via InvestorPlace
NVO Stock Alert: Novo Nordisk Pops on New Weight-Loss Drug
Novo Nordisk stock is gaining on Thursday as NVO investors react to positive news from its new weight loss drug clinical trial. 
Via InvestorPlace
Novo Nordisk's Stock Hits 52-Week High After Highly Sought After Obesity Drug Trial Data
Explore Novo Nordisk's Capital Markets Day insights! Uncover early trial success of amycretin, a potential obesity drug, with 13.1% weight loss in Phase 1. Learn about its safety and upcoming Phase 2... 
Via Benzinga
Novo Nordisk Jumps On Strong Results For New Weight-Loss Drug
Amycretin showed a 13.1% weight loss after 12 weeks in a phase 1 trial. 
Via Investor's Business Daily
Ozempic Maker Novo Nordisk To Introduce Obesity Drug Wegovy In Japan, Acknowledging Country's Rising Weight Issue
Novo Nordisk, a Danish pharmaceutical company, is set to launch its weight-loss drug, Wegovy, in Japan. This move is in response to the rising obesity rates in the country. 
Via Benzinga
What the Options Market Tells Us About Novo Nordisk
Via Benzinga
What the Options Market Tells Us About Novo Nordisk
Via Benzinga
Trillion-Dollar Threshold: The Next 3 Stocks Ready to Rise
With a trillion-dollar valuation in sight, these three growth companies have stocks ready to rise to meet the challenge. 
Via InvestorPlace
Novo Nordisk's Semaglutide's Multi-Beneficial Effects: Weight Loss, Improved Metabolic Markers, Liver Fat Reduction in HIV-Related Liver Disease
Novo Nordisk's Semaglutide, a breakthrough in HIV and fatty liver disease research, shows a 31% average reduction in liver fat. Novo Nordisk's trial reveals significant benefits for kidney health. 
Via Benzinga
Why Dexcom — And The Obesity Market — Could Benefit From This New FDA Win
The FDA granted Dexcom's Stelo a broad clearance, meaning people without diabetes can use it. 
Via Investor's Business Daily
Exposures Product Safety
Escalating Demand for Obesity Drugs Creates Time-Sensitive Race for Eli Lilly, Novo Nordisk
Eli Lilly's strategic collaborations with outsourcing partners for Zepbound (tirzepatide) production. Challenges persist as Eli Lilly and Novo Nordisk address production bottlenecks amid rising... 
Via Benzinga
Vivani Medical Surges on its Ozempic-Like Weight-Loss Implant
The Ozempic craze continues to make headlines in the medical sector, and GLP-1 drug stocks such as Vivani Medical continue to surge higher 
Via MarketBeat
Exposures Product Safety
Is Viking Therapeutics Stock a Better Buy Than Eli Lilly and Novo Nordisk After the Latest Weight-Loss Drug News?
A new player in the multibillion-dollar weight-loss drug market could be waiting in the wings. 
Via The Motley Fool
Why Novo Nordisk Stock Tumbled by Nearly 3% on Tuesday
The hotly popular European pharmaceutical company continues to investigate how its most popular molecule can be used for different afflictions. 
Via The Motley Fool
Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic
As President Biden prepares for his State of the Union address, he will address issues such as Bidenomics, healthcare, and the US's role in the world. 
Via Benzinga
Why Are Dialysis Provider Stocks Trading Higher On Tuesday?
Novo Nordisk's FLOW trial reveals a 24% reduction in kidney disease progression, cardiovascular events, and death with semaglutide 1.0 mg compared to placebo. Impact on dialysis stocks 
Via Benzinga
A New Competitor to Wegovy Could Be on the Way. Should Novo Nordisk Be Worried?
Here's why I'm not worried. 
Via The Motley Fool
Why Dialysis Stocks DaVita, Fresenius Soared On Novo's Ozempic News
Novo Nordisk tested its diabetes and weight-loss drug in patients with chronic kidney disease. 
Via Investor's Business Daily
Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why
Eli Lilly and Novo Nordisk dominate the diabetes market thanks to blockbuster medications Mounjaro, Ozempic, and Rybelsus. 
Via The Motley Fool
Novo Nordisk Says Famed Diabetes Medicine Ozempic Reduces Risk Of Kidney Disease Progression, Data Shows
Kidney outcomes trial results by Novo Nordisk. Semaglutide 1.0 mg shows a 24% reduction in kidney disease progression, cardiovascular events, and mortality risk in type 2 diabetes and CKD. 
Via Benzinga
Game Changers: 3 Biotech Stocks That Could Be Multibaggers in the Making
These three companies represent the world of biotech stocks and offer a unique blend of high risk and potentially high reward. 
Via InvestorPlace
Better Weight Loss Drug Stock: Viking Therapeutics vs. Eli Lilly
One is a reigning champion, and the other is a burgeoning contender. 
Via The Motley Fool
Jim Cramer Says Nvidia, Eli Lilly, Novo Nordisk Are Not Overvalued: 'Will Be Ready To Buy If This Market Sells Off'
Cramer suggested that the upcoming labor report could potentially trigger a buying opportunity, predicting stronger figures than expected by Wall Street. 
Via Benzinga
The Ozempic Diet Trend is Lifting These 2 Carnivore Stocks
The carnivore diet is back in the spotlight as people seek GLP-1 alternatives; here are two meat stocks that are moving higher on this trend 
Via MarketBeat
Better Blockbuster-Drug Stock: Novo Nordisk vs. Eli Lilly
This is a close contest, and it'll go on for at least a few more rounds. 
Via The Motley Fool
Missed Out on Novo Nordisk Stock? Buy This 1 Biotech Stock Right Now.
The battle for the obesity therapies market is escalating. 
Via The Motley Fool
3 Magnificent Growth Stocks to Buy in March
These three stocks have two important common denominators: the same industry and tremendous growth prospects. 
Via The Motley Fool
Why Novo Nordisk Stock Topped the Market Today
A favorite of both investors and analysts gets a boost from a bullish move by a pundit. 
Via The Motley Fool
Eli Lilly's Commercial Moat, Competitor Landscape: BofA Emphasizes Strength in Incretin Space, Undervalued Assets
Eli Lilly: BofA Securities rates it a top pick in Biopharma, with a YTD performance of +29%. Analysts highlight undervalued opportunities in heart disease, sleep apnea, and liver disease. Price target... 
Via Benzinga
Eli Lilly Stock And The Road To 1,000: Weight-Loss Drugs Could Generate $81 Billion
Wall Street isn't properly taking into account Lilly's next-generation drugs, an analyst says. 
Via Investor's Business Daily
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
68 69 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.